Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation
Open Access
- 28 October 2022
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 10 (10) , e004874
Abstract
Background: The loss of tumor antigens and depletion of CD8 T cells caused by the PD-1/PD-L1 pathway are important factors for tumor immune escape. In recent years, there has been increasing research on traditional Chinese medicine in tumor treatment. Cycloastragenol (CAG), an effective active molecule in Astragalus membranaceus, has been found to have antiviral, anti-aging, anti-inflammatory, and other functions. However, its antitumor effect and mechanism are not clear. Methods: The antitumor effect of CAG was investigated in MC38 and CT26 mouse transplanted tumor models. The antitumor effect of CAG was further analyzed via single-cell multiomics sequencing. Target responsive accessibility profiling technology was used to find the target protein of CAG. Subsequently, the antitumor mechanism of CAG was explored using confocal microscopy, coimmunoprecipitation and transfection of mutant plasmids. Finally, the combined antitumor effect of CAG and PD-1 antibodies in mice or organoids were investigated. Results: We found that CAG effectively inhibited tumor growth in vivo. Our single-cell multiomics atlas demonstrated that CAG promoted the presentation of tumor cell-surface antigens and was characterized by the enhanced killing function of CD8+ T cells. Mechanistically, CAG bound to its target protein cathepsin B, which then inhibited the lysosomal degradation of major histocompatibility complex I (MHC-I) and promoted the aggregation of MHC-I to the cell membrane, boosting the presentation of the tumor antigen. Meanwhile, the combination of CAG with PD-1 antibody effectively enhanced the tumor killing ability of CD8+ T cells in xenograft mice and colorectal cancer organoids. Conclusion: Our data reported for the first time that cathepsin B downregulation confers antitumor immunity and explicates the antitumor mechanism of natural product CAG.Keywords
Funding Information
- Natural Science Foundation Project of Shanghai, Scientific and Technological Innovation Action Plan (22ZR1447400)
- Jiangsu Higher Education Institutions and Mountain-Climbing Talents Project of Nanjing University (N/A)
- National Natural Science Foundation of China (81872877, 81930117, 82074318)
- National Key Research and Development Project (2017YFC1700602)
This publication has 49 references indexed in Scilit:
- Colorectal cancerNature Reviews Disease Primers, 2015
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastomaScience, 2014
- Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitis-associated cancerAutophagy, 2014
- The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cellsNature Biotechnology, 2014
- T cell antigen recognition at the cell membraneMolecular Immunology, 2012
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Telomerase-Based Pharmacologic Enhancement of Antiviral Function of Human CD8+ T LymphocytesThe Journal of Immunology, 2008
- Ectopic Expression of Vascular Cell Adhesion Molecule-1 as a New Mechanism for Tumor Immune EvasionCancer Research, 2007
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- Interplay between the TCR/CD3 Complex and CD4 or CD8 in the Activation of Cytotoxic T LymphocytesImmunological Reviews, 1989